True North Therapeutics Inks $35M Series B

What does True North Therapeutics do?

True North Therapeutics, is a pioneering biotechnology company which selectively inhibits the complement pathway for diseases with high unmet clinical necessity. True North Therapuetics’s monoclonal antibody, TNT009, targets the Classical Complement Pathway, enabling the selective inhibition of downstream phagocytosis, cell lysis and inflammation. This biotech company is currently focusing on Complement  mediated rare diseases in dermatology, kidney transplant, hematologic and neurological space.

Ture North Therapeutics develops novel therapies which selectively inhibits the Complement system for treating rare diseases.

How much True North Therapeutics was funded?

The biotech company has raised $35 M in Series B round from Baxter Vnetures, MPM Capital, SR One, Kleiner Perkins Caufield & Byers and OrbiMed

Previous Funding

• $22Min  Series A funding on June 17^th, 2014.

What is next for True North Therapeutics?

The latest funding will be use to advance multiple product candidates from Ture North Theraputics’s Research and Dvelopment engine which targets the Complement system, including implementation of the TNT009 broad clinical program.

The latest fund will provide the company funding to finish its clinical studies of TNT009 in multiple indications for the Complement mediated rare diseases and to advance a 2^nd drug candidate from its preclinical pipeline into clinical development.

More about True North Therapeutics.

True North Therapeutics the biotechnology company which is developing a pipeline of novel therapies was founded in 2013 by Nancy Stagliano with its headquarters located in South Francisco, California. The biotech company selectively targets the complement pathway of the immune system for addressing fundamental mechanisms in rare diseases along with those with high unmet need. True North Therapeutics is the first company to use the power of selective targeting of the Complement pathway to address rare diseases which have either very few treatment options or no approved therapies at all. The company has also plans to address rare diseases in dermatology, hematology and kidney transplant departments.